This Congress Hub brings you the latest updates on Mantle Cell Lymphoma (MCL) from the American Society of Hematology (ASH) Annual Meeting & Exposition 2023, and the European Hematology Association (EHA) Hybrid Congress 2024.

Complexities and evolving treatment modalities of Mantle Cell Lymphoma

Pivotal discussions from the EHA Congress, providing a comprehensive overview of the current state and future directions in MCL management. From the front lines of first-line treatment to the complexities of Relapsed Refractory MCL, our Faculty explore how emerging therapies are reshaping the standard of care and offering new hope to patients worldwide.

Infographic summarizing discussion on the diagnosis and emerging treatment approaches for mantle cell lymphoma (MCL).

Highlights from the ASH Congress on ‘Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas’ held from December 6th to 15th 2023.

Outcomes for new treatment combinations in Mantle Cell Lymphoma: focus on Sympatico and BOVen trials

Key opinion leaders, Professor Tarec El-Galaly and Professor Martin Dreyling analyse efficacy and tolerability data for new treatment regimens for Mantle Cell Lymphoma from key trials presented at ASH 2023.

Information from these videos will provide knowledge for health care professionals on new, targeted treatment combinations for patients with Mantle Cell Lymphoma to enable optimal disease prognosis.

Article providing key insights and perspectives on the various prognostic factors, different clinical trials, as well as progress in treatment outcomes of MCL patients.

Highlights from the 65th 2023 American Society of Hematology (ASH) Annual Meeting & Exposition on Blood and Bone Marrow Disorders and some sessions dedicated to ‘Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas’